IMMX - Immix Biopharma, Inc. Common Stock Stock Price, Fair Value and News

2.36USD+0.11 (+4.89%)Delayed as of 17 May 2024, 01:10 pm ET

Market Summary

USD2.36+0.11

Delayedas of 17 May 2024, 01:10 pm

4.89%

IMMX Stock Price

View Fullscreen

IMMX RSI Chart

IMMX Valuation

Market Cap

59.4M

Price/Earnings (Trailing)

-3.26

EV/EBITDA

-1.64

Price/Free Cashflow

-4.52

MarketCap/EBT

-3.23

IMMX Price/Earnings (Trailing)

IMMX Profitability

Return on Equity

-65.89%

Return on Assets

-53.01%

Free Cashflow Yield

-22.14%

IMMX Fundamentals

IMMX Earnings

Earnings (TTM)

-18.2M

Earnings Growth (Yr)

-110.53%

Earnings Growth (Qtr)

-3.74%

Breaking Down IMMX Revenue

52 Week Range

1.404.51

(Low)(High)

Last 7 days

3.2%

Last 30 days

-12.4%

Last 90 days

-29.5%

Trailing 12 Months

27.1%

How does IMMX drawdown profile look like?

IMMX Financial Health

Current Ratio

5.82

IMMX Investor Care

Shares Dilution (1Y)

75.71%

Diluted EPS (TTM)

-0.93

Tracking the Latest Insider Buys and Sells of Immix Biopharma, Inc. Common Stock

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 11, 2023	hsu jason	bought	144,894	4.674	31,000	-
Dec 08, 2023	hsu jason	bought	122,025	4.881	25,000	-
Sep 15, 2023	hsu jason	bought	17,396	2.4852	7,000	-
Sep 14, 2023	hsu jason	bought	25,772	2.5772	10,000	-
Sep 14, 2023	ng carey	bought	25,760	2.576	10,000	-
Sep 12, 2023	hsu jason	bought	84,864	2.8288	30,000	-
Sep 12, 2023	adams helen c.	bought	38,491	2.9609	13,000	-
Sep 11, 2023	hsu jason	bought	72,280	2.8912	25,000	-
Sep 08, 2023	hsu jason	bought	25,317	2.5317	10,000	-
Sep 07, 2023	buchan melissa jane	bought	49,226	2.4613	20,000	-

Which funds bought or sold IMMX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-165,396	131,887	-%
May 15, 2024	Royal Bank of Canada	reduced	-91.18	-	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	new	-	70,186	70,186	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	166,643	166,643	-%
May 15, 2024	CORSAIR CAPITAL MANAGEMENT, L.P.	new	-	213,012	213,012	0.06%
May 15, 2024	Tower Research Capital LLC (TRC)	added	887	13,494	17,487	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	new	-	4,580	4,580	-%
May 15, 2024	Walleye Capital LLC	new	-	67,313	67,313	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-11,031	-	-%
May 15, 2024	MORGAN STANLEY	added	234	54,035	165,918	-%

Are Funds Buying or Selling IMMX?

Are funds buying IMMX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IMMX

No. of Funds

Unveiling Immix Biopharma, Inc. Common Stock's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 07, 2024	hirschman orin	5.8%	1,455,000	SC 13G
Aug 30, 2023	gkcc, llc	19.99%	3,255,734	SC 13D

Recent SEC filings of Immix Biopharma, Inc. Common Stock

View All Filings

Date Filed	Form Type	Document
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 09, 2024	10-Q	Quarterly Report
Apr 30, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Mar 29, 2024	10-K	Annual Report
Feb 20, 2024	S-8	Employee Benefits Plan
Feb 07, 2024	SC 13G	Major Ownership Report
Feb 07, 2024	424B5	Prospectus Filed

Peers (Alternatives to Immix Biopharma, Inc. Common Stock)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Immix Biopharma, Inc. Common Stock News

Latest updates

Immix Biopharma, Inc. Common Stock Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	72.4%	34.00	20.00	22.00	16.00	13.00	15.00	17.00	19.00	20.00	18.00	-
Current Assets	66.3%	33.00	20.00	22.00	16.00	13.00	15.00	17.00	19.00	20.00	18.00	1.00
Cash Equivalents	67.4%	29.00	18.00	20.00	13.00	11.00	13.00	17.00	18.00	19.00	18.00	0.00
Net PPE	619.1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	80.4%	7.00	4.00	3.00	2.00	1.00	2.00	1.00	1.00	0.00	0.00	5.00
Current Liabilities	52.0%	6.00	4.00	3.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00	5.00
Shareholder's Equity	68.4%	28.00	16.00	20.00	13.00	12.00	13.00	17.00	18.00	20.00	18.00	-
Retained Earnings	-9.8%	-58.67	-53.41	-48.32	-44.04	-40.46	-37.99	-34.19	-32.65	-31.09	-29.76	-5.37
Additional Paid-In Capital	24.1%	87.00	70.00	68.00	57.00	52.00	51.00	51.00	51.00	51.00	48.00	1.00
Shares Outstanding	32.5%	26.00	20.00	20.00	16.00	14.00	14.00	14.00	14.00	14.00	13.00	3.00
Minority Interest	-40.4%	-0.28	-0.20	-0.12	-0.06	-0.03	-	-	-	-	-	-
Float	-	-	-	-	28.00	-	-	-	18.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Cashflow From Operations	-42.9%	-3,826	-2,677	-3,086	-3,515	-2,092	-3,903	-1,462	-547	-1,494	-1,114	-50.76	-158	-266	-
Share Based Compensation	-10.2%	943	1,051	737	448	330	230	213	116	65.00	122	62.00	31.00	4.00	-
Cashflow From Investing	-2191.2%	-301	-13.18	-	-	-	-	-	-	-	-	-	-	-802*	-
Cashflow From Financing	2618.4%	15,949	587	10,066	4,692	119	424	-	-105	2,914	18,720	-18.35	82.00	65.00	-
Buy Backs	-	-	-	-	-	-	44.00	-	56.00	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IMMX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
General and administrative expenses	$ 2,341,464	$ 1,201,734
Research and development	3,248,669	1,319,020
Total operating expenses	5,590,133	2,520,754
Loss from operations	(5,590,133)	(2,520,754)
Other income (expense):
Interest income	267,908	27,892
Total other income (expense), net	267,908	27,892
Loss before provision for income taxes	(5,322,225)	(2,492,862)
Provision for income taxes	8,839	5,170
Net loss	(5,331,064)	(2,498,032)
Net loss attributable to non-controlling interests	72,073	18,368
Net loss attributable to Immix Biopharma, Inc. common stockholders	(5,258,991)	(2,479,664)
Other comprehensive income (loss):
Foreign currency translation	(45,052)	(4,474)
Total other comprehensive loss	(45,052)	(4,474)
Comprehensive loss	(5,304,043)	(2,484,138)
Less: comprehensive loss attributable to non-controlling interests
Comprehensive loss attributable to Immix Biopharma, Inc. common stockholders	$ (5,304,043)	$ (2,484,138)
Loss per common share - basic	$ (0.22)	$ (0.18)
Loss per common share - diluted	$ (0.22)	$ (0.18)
Weighted average shares outstanding - basic	23,438,143	13,897,184
Weighted average shares outstanding - diluted	23,438,143	13,897,184

IMMX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 29,319,233	$ 17,509,791
Tax receivable	2,024,726	1,172,183
Prepaid expenses and other current assets	1,571,303	1,105,776
Total current assets	32,915,262	19,787,750
Other assets	20,418
Deferred offering cost		87,229
Right-of-use asset, net	1,051,078
Property and equipment, net	360,834	50,181
Total assets	34,347,592	19,925,160
Current liabilities:
Accounts payable and accrued expenses	5,622,501	3,721,783
Operating lease liability - current	34,284
Total current liabilities	5,656,785	3,721,783
Operating lease liability – long term	1,058,944
Total liabilities	6,715,729	3,721,783
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value; 200,000,000 shares authorized; 26,468,783 shares issued and 26,396,420 shares outstanding at March 31, 2024 and 19,994,719 shares issued and 19,922,356 shares outstanding at December 31, 2023	2,648	2,000
Additional paid-in capital	86,593,132	69,779,706
Accumulated other comprehensive income	89,614	134,666
Accumulated deficit	(58,670,286)	(53,411,295)
Treasury stock at cost, 72,363 shares as of March 31, 2024 and December 31, 2023	(99,963)	(99,963)
Total Immix Biopharma, Inc. stockholders’ equity	27,915,145	16,405,114
Non-controlling interests	(283,282)	(201,737)
Total stockholders’ equity	27,631,863	16,203,377
Total liabilities and stockholders’ equity	$ 34,347,592	$ 19,925,160

About Immix Biopharma, Inc. Common Stock

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
WEBSITE	immixbio.com
INDUSTRY	Biotechnology
EMPLOYEES	9

Immix Biopharma, Inc. Common Stock Frequently Asked Questions

What is the ticker symbol for Immix Biopharma, Inc. Common Stock? What does IMMX stand for in stocks?

IMMX is the stock ticker symbol of Immix Biopharma, Inc. Common Stock. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Immix Biopharma, Inc. Common Stock (IMMX)?

As of Thu May 16 2024, market cap of Immix Biopharma, Inc. Common Stock is 59.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMMX stock?

You can check IMMX's fair value in chart for subscribers.

What is the fair value of IMMX stock?

You can check IMMX's fair value in chart for subscribers. The fair value of Immix Biopharma, Inc. Common Stock is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Immix Biopharma, Inc. Common Stock is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IMMX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Immix Biopharma, Inc. Common Stock a good stock to buy?

The fair value guage provides a quick view whether IMMX is over valued or under valued. Whether Immix Biopharma, Inc. Common Stock is cheap or expensive depends on the assumptions which impact Immix Biopharma, Inc. Common Stock's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMMX.